Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), have been suggested to act as β-cell growth factors and may therefore be of critical importance for the maintenance of a proper β-cell mass. We have investigated the molecular mechanism of incretin-induced β-cell replication in primary monolayer cultures of newborn rat islet cells. GLP-1, GIP and the long-acting GLP-1 derivative, lira-glutide, increased β-cell replication 50–80% at 10–100 nM upon a 24 h stimulus, whereas glucagon at a similar concentration had no significant effect. The stimulatory effect of GLP-1 and GIP was efficiently mimicked by the adenylate cyclase activator, forskolin, at 10 nM (~90% increase) and was additive (~170–250% increase) with the growth response to human growth hormone (hGH), indicating the use of distinct intracellular signalling pathways leading to mitosis by incretins and cytokines, respectively. The response to both GLP-1 and GIP was completely blocked by the protein kinase A (PKA) inhibitor, H89. In addition, the phosphoinositol 3-kinase (PI3K) inhibitor wortmannin and the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059, both inhibited GLP-1- and GIP-stimulated proliferation. The p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, had no inhibitory effect on either GLP-1 or GIP stimulated proliferation. Cyclin Ds act as molecular switches for the G0/G1-S phase transition in many cell types and we have previously demonstrated hGH-induced cyclin D2 expression in the insulinoma cell line, INS-1. GLP-1 time-dependently induced the cyclin D1 mRNA and protein levels in INS-1E, whereas the cyclin D2 levels were unaffected. However, minor effect of GLP-1 stimulation was observed on the cyclin D3 mRNA levels. Transient transfection of a cyclin D1 promoter-luciferase reporter construct into islet monolayer cells or INS-1 cells revealed approximately a 2–3 fold increase of transcriptional activity in response to GLP-1 and GIP, and a 4–7 fold increase in response to forskolin. However, treatment of either cell type with hGH had no effect on cyclin D1 promoter activity. The stimulation of the cyclin D1 promoter by GLP-1 was inhibited by H89, wortmannin, and PD98059. We conclude that incretin-induced β-cell replication is dependent on cAMP/PKA, p42 MAPK and PI3K activities, which may involve transcriptional induction of cyclin D1. GLP-1, GIP and liraglutide may have the potential to increase β-cell replication in humans which would have significant impact on long-term diabetes treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 1×
“Un-phosphorylated GSK-3 is involved in mediating proteasomal cyclin D1 degradation and has been shown to inhibit cyclin D1 transcription (Diehl et al. 1998).”
BackgroundRane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700 · cited 1×
“An important role of these proteins in -cell mass regulation is suggested by the finding that Cdk-4 knockout mice carry a diabetic phenotype, whereas knockin of a constitutive active Cdk-4 mutant is associated with -cell hyperplasia (Rane et al. 1999).”
BackgroundMice lacking cyclin D1 are small and show defects in eye and mammary gland development.
Fantl, V, Stamp, G., Andrews, A., Rosewell, I., & Dickson, C. (1995) · Genes & Development · doi:10.1101/gad.9.19.2364 · Cited by 691
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 2×
“The role of incretins as regulators of -cell replication (Farilla et al. 2003) and anti-apoptosis that have been recently described (Hui et al. 2003, Urusova et al. 2004, Bregenholt et al. 2005) may be of particular importance since functional -cells are progressively lost during development of…”
BackgroundButeau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 5×
“2001), and up-regulation of the DNA-binding activity of the transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1), has been suggested to play a role in GLP-1 induced DNA-synthesis and regulation of both the insulin gene and genes encoding metabolic enzymes (Buteau et al. 1999).”
BackgroundMethodResultInfluentialCyclins D2 and D1 Are Essential for Postnatal Pancreatic β-Cell Growth
Kushner, J. A., Ciemerych, M. A., Sicinska, E., Wartschow, L. M., Teta, M., Long, S. Y., Sicinski, P., & White, M. F. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3752-3762.2005 · Cited by 334 · cited 1×
“Moreover, recent data from knockout mice presented by Kushner et al (2005), indicates that cyclin D3 plays a minor role in promoting islet function compared with cyclin D1 and D2.”
BackgroundMoens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250 · cited 2×
“Both glucagon, GLP-1, and GIP receptors are expressed on pancreatic -cells (Moens et al. 1996).”
BackgroundFriedrichsen, B. N., Richter, H. E., Hansen, J. A., Rhodes, C. J., Nielsen, J. H., Billestrup, N., & Møldrup, A. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0356 · Cited by 93 · cited 6×
“…of Marburg, Marburg, Germany) along with the internal control plasmid TKrenilla (Promega) were transiently transfected into islet monolayer or INS-1E cells using LipofectAMINE 2000 (Invitrogen Life Technologies) as previously described (Friedrichsen et al. 2003) using 2 µl Lipofect AMINE 2000/well.”
BackgroundMethodInfluentialSelf-citationHussain, M. A., Daniel, P. B., & Habener, J. F. (2000) · Diabetes · doi:10.2337/diabetes.49.10.1681 · Cited by 40 · cited 1×
“Interestingly, glucagon but neither GLP-1 nor pituitary adenylyl cyclase-activating peptide were found to stimulate the expression of the transcriptional repressor inducible cAMP early repressor in pancreatic -cells (Hussain et al. 2000).”
Background
Cited by
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“In agreement with this result, GLP-1R activation has been shown to up-regulate the expression of cyclin D1 (Friedrichsen et al., 2006; Kim et al., 2006), and this effect is likely to be mediated by PKA-dependent activation of CREB (Kim et al.”
BackgroundGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Liu, Z., & Habener, J. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706105200 · Cited by 326
Metadata
- Authors
- Friedrichsen, B. N., Neubauer, N., Lee, Y. C., Gram, V. K., Blume, N., Petersen, J. S., Nielsen, J. H., & Møldrup, A.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2006-03
- Volume
- 188
- Issue
- 3
- Pages
- 481-492
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2132051907
- Cited by
- 147
- References
- 9
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.